Earnings Preview For Phibro Animal Health
Phibro Animal Health (NASDAQ:PAHC) is gearing up to announce its quarterly earnings on Wednesday, 2026-02-04. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Phibro Animal Health will report an earnings per share (EPS) of $0.68.
Investors in Phibro Animal Health are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Performance in Previous Earnings
The company's EPS beat by $0.13 in the last quarter, leading to a 4.59% increase in the share price on the following day.
Here's a look at Phibro Animal Health's past performance and the resulting price change:
| Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|
| EPS Estimate | 0.60 | 0.52 | 0.53 | 0.45 |
| EPS Actual | 0.73 | 0.57 | 0.63 | 0.54 |
| Price Change % | 5.00 | 19.00 | 15.00 | 10.00 |
Stock Performance
Shares of Phibro Animal Health were trading at $41.91 as of February 02. Over the last 52-week period, shares are up 82.61%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Analyst Views on Phibro Animal Health
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Phibro Animal Health.
The consensus rating for Phibro Animal Health is Outperform, derived from 1 analyst ratings. An average one-year price target of $50.0 implies a potential 19.3% upside.
Peer Ratings Comparison
In this comparison, we explore the analyst ratings and average 1-year price targets of Harrow, Innoviva and ANI Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.
- Analysts currently favor an Buy trajectory for Harrow, with an average 1-year price target of $67.5, suggesting a potential 61.06% upside.
- Analysts currently favor an Buy trajectory for Innoviva, with an average 1-year price target of $38.5, suggesting a potential 8.14% downside.
- Analysts currently favor an Buy trajectory for ANI Pharmaceuticals, with an average 1-year price target of $113.0, suggesting a potential 169.63% upside.
Peer Metrics Summary
In the peer analysis summary, key metrics for Harrow, Innoviva and ANI Pharmaceuticals are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Phibro Animal Health | Outperform | 39.73% | $119.78M | 8.88% |
| Harrow | Buy | 45.44% | $53.93M | 2.11% |
| Innoviva | Buy | 20.44% | $75.54M | 10.43% |
| ANI Pharmaceuticals | Buy | 53.58% | $134.42M | 5.57% |
Key Takeaway:
Phibro Animal Health ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Phibro Animal Health is at the bottom compared to its peers.
Unveiling the Story Behind Phibro Animal Health
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Phibro Animal Health: Delving into Financials
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Phibro Animal Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.73% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Phibro Animal Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.29%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 8.88%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Phibro Animal Health's ROA excels beyond industry benchmarks, reaching 1.93%. This signifies efficient management of assets and strong financial health.
Debt Management: Phibro Animal Health's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.52, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
To track all earnings releases for Phibro Animal Health visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.